Outcomes following stereotactic body radiotherapy for patients with Child-Pugh B/C hepatocellular carcinoma.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 167-167
Author(s):  
Shaelyn Culleton ◽  
Haiyan Jiang ◽  
Joon-Hyung J. Kim ◽  
James D. Brierley ◽  
Anthony M. Brade ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Liver Function ◽  
Median Survival ◽  
Stereotactic Body Radiotherapy ◽  
Liver Volume ◽  
Impaired Liver Function ◽  
Bridge To Transplant ◽  
Local Progression ◽  
Impaired Liver

167 Background: Assessment of outcomes in patients with hepatocellular carcinoma (HCC) and Child-Pugh B or C liver function treated with stereotactic body radiotherapy (SBRT). Methods: From 2004 – July 2012, 39 patients with HCC and Child-Pugh B/C liver function were treated with SBRT. Inclusion criteria included Child-Pugh B/C, treatment with SBRT, 5 to 15 fractions, and radical or palliative intent. Univariate analyses (UVA) were performed to assess relationships of patient demographics, liver function tests and treatment characteristics on overall survival (OS) and time to progression (TTP). Results: The majority of the 39 patients had Child-Pugh B7 liver function (69%), performance status ECOG 0-1 (82%), radiological evidence of tumor vascular thrombosis (62%) and hepatitis C as underlying liver disease (49%). 10 patients treated as bridge-to-transplant. The median dose was 3300 cGy in 6 fractions (range: 2000-4500 cGy in 5-15 fractions), individualized based on spared liver volume and underlying liver function. The median survival for all patients was 9.9 months (95% CI: 3.4-18.4). UVA demonstrated significantly reduced survival with Child-Pugh score > B7, baseline AFP > 1049 ng/mL (upper quartile) and gross tumor volume > 93 cm3. The median survival of patients treated with SBRT as a bridge-to-transplant versus the non-bridge-to–transplant patients was 30.7 months (95% CI: 0.6-not reached) versus 7.9 months (95% CI: 3.4-15.1; p=0.008). No HCC tumors treated with SBRT demonstrated local progression during the follow-up time. The median TTP for all patients was 18.8 months (95% CI: 6.2-not reached). Model for end stage liver disease (MELD) score > 12 was the only factor associated with reduced TTP on UVA. 31% of patients had a decline in Child-Pugh score by 2 or more points at 3 months. No acute treatment related toxicities of grade 3 or higher were reported. Conclusions: SBRT may be considered as a treatment option for HCC with impaired liver function. Survival is best in patients who are treated as a bridge-to-transplant, have smaller tumors, are Child-Pugh class B7, and have lower AFP levels. Randomized trials of radiation therapy in HCC patients with impaired liver function are warranted.

Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma

1985 ◽  
Vol 54 (03) ◽  
pp. 617-618 ◽  
Author(s):  
J C Kirchheimer ◽  
K Huber ◽  
P Polterauer ◽  
B R Binder
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Liver Function ◽  
Matched Control ◽  
Malignant Growth ◽  
Control Groups ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Specific Medication ◽  
History Of

SummaryPlasma urokinase antigen levels were studied in 78 patients suffering from liver diseases. Blood was drawn before any specific medication was initiated. Impairment of liver function was comparable in all patients. In both groups of cirrhotic liver disease (alcoholic and non-alcoholic), normal levels of plasma urokinase antigen were found as compared to age-matched control groups. In both groups of patients with hepatomas (with or without a history of liver cirrhosis), however, significantly increased plasma urokinase antigen levels could be determined. These data indicate that an increase in plasma urokinase antigen might rather relate to malignant growth in liver disease than to impaired liver function.

scholarly journals Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation?

HPB ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 244-250 ◽  
Author(s):  
Takanobu Yamao ◽  
Katsunori Imai ◽  
Yo-ichi Yamashita ◽  
Takayoshi Kaida ◽  
Shigeki Nakagawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Treatment ◽  
Radiofrequency Ablation ◽  
Liver Function ◽  
Hepatic Resection ◽  
Treatment Strategy ◽  
Impaired Liver Function ◽  
Impaired Liver

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2

2017 ◽  
Vol 35 (6) ◽  
pp. 589-597 ◽  
Author(s):  
Tadaaki Arizumi ◽  
Tomohiro Minami ◽  
Hirokazu Chishina ◽  
Masashi Kono ◽  
Masahiro Takita ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Liver Function ◽  
Transcatheter Arterial Chemoembolization ◽  
Time To Progression ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Tace Treatment ◽  
Arterial Chemoembolization

Background: Transarterial chemoembolization (TACE) is recommended for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B. However, because of the heterogeneity of HCC in BCLC stage B; various subclassification systems have been proposed to predict the prognosis of patients. Previously, we proposed the Kinki criteria for precise classification of HCC cases in BCLC stage B. In this study, we compared the time to TACE refractoriness in HCC patients with Kinki criteria substages B1 and B2-HCC. Summary: Between January 2006 and December 2013, 592 HCC patients (substage B1, n = 118; substage B2, n = 170) underwent TACE. Time to progression under TACE treatment was defined as the time to untreatable progression (TTUP). TTUP and changes in liver function were analyzed in patients with substages B1 and B2-HCC. The median TTUP was 25.7 months (95% CI 19.3-37.3) and 16.4 months (95% CI 13.1-20.2) in patients with substage B1-HCC and substage B2-HCC, respectively (p = 0.0050). In patients with substage B2-HCC, median Child-Pugh scores after the first TACE session was significantly different from those after third and fifth TACE sessions (first-third, p = 0.0020; first-fifth, p = 0.0008). Key Message: TACE refractoriness occurred earlier in patients with substage B2-HCC than those with substage B1-HCC; deterioration of liver function with repeated TACE was more obvious in HCC cases with stage-B1 tumor. Shorter TTUP and impaired liver function due to repeated TACE could be responsible for the shorter survival in patients with substage B2-HCC.

Hepatic resection of hepatocellular carcinoma in cirrhotic livers: Is it unjustified in impaired liver function?

Surgery ◽  
1996 ◽  
Vol 120 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Cheng-Chung Wu ◽  
Willam-Lin Ho ◽  
Da-Cheng Yeh ◽  
Chi-Ren Huang ◽  
Tse-Jia Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Hepatic Resection ◽  
Impaired Liver Function ◽  
Impaired Liver

scholarly journals HUBUNGAN KONSUMSI ALKOHOL DENGAN GANGGUAN FUNGSI HATI PADA SUBJEK PRIA DEWASA MUDA DI KELURAHAN TATELI DAN TELING ATAS MANADO

e-CliniC ◽  
2014 ◽  
Vol 2 (2) ◽  
Author(s):  
Dicky Conreng ◽  
B. J. Waleleng ◽  
Stella Palar
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Alcohol Consumption ◽  
Liver Function ◽  
Alcoholic Liver Disease ◽  
Impaired Liver Function ◽  
The Third ◽  
Impaired Liver ◽  
Keywords Alcohol ◽  
The World

Abstract: Alcohol consumption is the third biggest risk factor as a cause of disease and disability in the world, and is the biggest risk factor in America and second biggest in Europe as the cause of disease and disability. Alcohol is a causalfactorin 60 types of diseases and injuries and a component cause in 200 others. There are many diseases that is caused by alcohol consumption, one of them causes impaired liver function, such as alcoholic liver disease. However according to the theory, not all alcoholics will have an impaired liver function, so this reasearch was done to confirm that theory. Alcoholism will be measured by the AUDIT questionnaire and the impaired liver function will be measured by the increase in the GGT enzyme. Conclusion: Not all chronic alcoholics will have impaired liver function with the same amount of alcohol consumption. Keywords: alcohol, impaired liver function, alcoholic liver disease, AUDIT, GGT.     Abstrak: Konsumsi alkohol merupakan faktor risiko terbesar ketiga di dunia sebagai penyebab penyakit dan disabilitas, dan merupakan faktor risiko terbesar pertama di Amerika serta faktor risiko terbesar kedua di Eropa sebagai penyebab penyakit dan disabilitas. Alkohol merupakan faktor penyebab dari sekitar 60 jenis penyakit dan merupakan faktor komponen dari 200 jenis penyakit lainnya. Terdapat berbagai jenis penyakit yang disebabkan oleh konsumsi alkohol, salah satunya adalah gangguan fungsi hati seperti penyakit hati alkoholik (alcoholic liver disease). Namun menurut teori tidak semua peminum alkohol akan mengalami gangguan fungsi hati, sehingga penelitian ini dilakukan untuk memastikan teori tersebut. Gangguan konsumsi alkohol akan diperiksa menggunakan kuesioner AUDIT dan gangguan fungsi hati akan diperiksa melalui peningkatan enzim GGT. Simpulan: Tidak semua peminum alkohol kronik akan mengalami gangguan fungsi hati dengan jumlah konsumsi alkohol yang sama. Kata kunci: alkohol, gangguan fungsi hati, penyakit hati alkoholik, AUDIT, GGT.

Sign in / Sign up

Export Citation Format

Share Document